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Background and Purpose A nested case-control analysis of data collected during the prospective Royal College of General Practitioners' Oral Contraception Study was performed to examine the relation between use of oral contraception and risk of stroke.
Methods The 253 women who had a first-ever stroke (International Classification of Diseases, eighth revision, codes 4300 to 4389) or amaurosis fugax (code 3791) between 1968 and 1990 (case subjects) were compared with 759 women who did not have this diagnosis (control subjects).
Results Smoking, social class, and history of hypertension were found to be important risk factors for stroke. Women who had ever used oral contraceptives had an increased risk of all stroke (odds ratio, 1.5; 95% confidence interval, 1.1 to 2.0, I n 1977 the Royal College of General Practitioners' (RCGP) Oral Contraception Study reported an increased risk of fatal stroke, especially subarachnoid hemorrhage, among women who had previously used oral contraceptives. 1 The following year the Walnut Creek Contraceptive Drug Study also reported an increased incidence of subarachnoid hemorrhage among former users. 2 A number of subsequent investigations, however, failed to demonstrate a risk in either former users or those who had ever used the pill (ever users). 3 -8 Any residual effects would have important public health implications because most sexually active women use the pill at some time, 9 and the incidence of cerebrovascular disease increases substantially after menopause.
A study of risk factors for stroke in women has been conducted using a nested case-control analysis of data reported to the RCGP Oral Contraception Study up to January 1990. We report here the findings with respect to oral contraception.
Subjects and Methods
The RCGP Oral Contraception Study was established as a cohort of 23 000 women who were using the pill and a similar number who had never used this method of contraception. The women were recruited by 1400 general practitioners throughout the United Kingdom during 1968 and 1969. 10 Most (98%)
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Correspondence to Dr Philip C. Hannaford, Royal College of General Practitioners, Manchester Research Unit, Parkway House, Palatine Rd, Northenden, Manchester, M22 4DB, UK adjusted for smoking and social class) and of a fatal event (adjusted odds ratio, 2.3; 95% confidence interval, 1.2 to 4.4). A significant doubling of all stroke risk was observed among current users, an effect that was apparent in both smokers and nonsmokers. Former users had a small nonsignificant elevation in risk of all stroke but a stronger risk of a fatal event. The effects in former users appeared to be restricted to women who smoked.
Conclusions Current users of oral contraceptives appeared to be at increased risk of stroke. There is some evidence that former users may also have a persisting effect, although further research is needed to confirm these observations. (Stroke.
1994-^5:935-942.)
Key Words • contraception, oral • risk factors • women of the women were white, and all were married or living as married. At regular intervals the doctors supply comprehensive information about any hormonal preparations prescribed, all new episodes of morbidity, and causes of death.
All women who had a stroke (International Classification of Diseases [ICD] , eighth revision, codes 4300 to 4389) or episode of amaurosis fugax (ICD 3791) between 1968 and 1990 were identified from the Oral Contraception Study database. The diagnosis was that reported by the general practitioner.
There were 315 potential cases, of which 62 (20%) were excluded for a variety of reasons, including history of cerebrovascular disease before recruitment to the main cohort study, malignancy before the stroke, diagnosis of hypertensive encephalopathy, vertebrobasilar insufficiency, or drop attack (Table 1) . Information about social class or smoking was not available for five case subjects, and these women were also excluded.
Each case subject (index subject) was age matched with three control subjects selected from the Oral Contraception Study database using a procedure similar to that used in a previous study. 11 A potential source of bias could have occurred if control subjects were selected from the same general practitioner as the index subject, because in the main study each pill user had been recruited with an age-matched nonuser. Therefore, we excluded the index subject's doctor when sampling for control subjects. The sampling procedure was carried out in two stages. First, three participating general practitioners were identified by random selection for each case. Details of their recruited subjects were then examined to find those who had a date of birth within 2 years of the index subject's date of birth, had no documented history of cerebrovascular disease or malignancy, and were still under observation in the cohort study at the date the stroke was diagnosed in the index subject. From those eligible, one control subject was randomly selected for each doctor. If there were no suitable control subjects, another doctor was randomly selected. The medical exclusion criteria for case subjects were also applied to the control subjects. Three women initially identified as potential control subjects had a history of stroke before recruitment to the main study, and 23 had a malignancy before the date when their matching index subject suffered her stroke. All these women were replaced with other eligible subjects.
The records of all selected subjects were examined and their personal characteristics, details of their use of the pill, and medical history extracted and categorized. Within each matched set all characteristics were those that pertained at the date of the index subject's diagnosis except smoking status, which was recorded only at recruitment to the main cohort study. For the five control subjects who had missing smoking data and 14 who had missing social class information, the respective value of the matched index subject was substituted. Although this would tend to underestimate the odds ratios (ORs) associated with these factors, the effect was negligible.
Factors examined in this study were social class (based on the occupation of the woman's husband), parity, smoking, use of oral contraceptives, history of hypertension (ICD 4010), or toxemia of pregnancy (ICD 6370, 6371, or 6379) before the stroke. In this article "all events" refers to all first-ever fatal or nonfatal cases combined; "fatal events" refers to the subgroup of case subjects who died within 6 months of their first stroke without evidence of an alternative cause.
Power and Statistical Analysis
The 253 matched sets were evaluated using the program for conditional logistic regression analysis of matched case-control data, available in EGRET. 12 Each variable was first examined separately, and unadjusted ORs were calculated. These were then adjusted for social class, smoking, and history of use of the pill, and confidence intervals (CIs) were calculated. CIs for the case-fatality rates were calculated using the CONFIDENCE INTERVAL ANALYSIS PROGRAM. 13 For 250 case subjects a ratio of three control subjects for each case subject gave a power of more than 90% to detect a doubling of risk, with an exposure prevalence of 10% among the control subjects (a=.05, two sided).
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Results
The age of the index subjects ranged from 21 to 70 yean (median, 45.4 years). Table 2 shows the effects of factors other than the pill on the risk of first-ever stroke; smoking, lower social class, and history of hypertension were associated with an increased risk. Women who smoked had more than twice the risk of stroke compared with nonsmokers (adjusted OR, 2.2; 95% CI, 1.7 to 3.0), and there was a strong positive trend with the number of cigarettes smoked. Social class was inversely related to risk of stroke, with a clear linear trend that was independent of smoking. Parity and previous toxemia of pregnancy appeared not to materially alter the risk of stroke.
The association between use of oral contraception and stroke is summarized in Table 3 . When all events (fatal and nonfatal) were considered, women who had ever used the pill were found to have a significantly elevated risk of stroke (adjusted OR, 1.5; 95% CI, 1.1 to 2.0). The estimated risk of stroke among current users was 2.5 compared with 1.3 among former users. Ever use of the pill more than doubled the risk of fatal stroke (adjusted OR, 2.3; 95% CI, 1.2 to 4.4). This association was similar in both current and former users (adjusted ORs, 1.8 and 2.4, respectively). Adjustment of the crude ORs for the potential confounding effects of smoking and social class made little difference in the size of the risk estimates.
Most of the fatal events were hemorrhagic in nature (Table 4 ). In both subarachnoid and cerebral hemorrhagic stroke, the estimates of risk for each category of pill user (ever, current, or former) relative to those who had never used the pill (never users) were greater when fatal events were examined compared with all events combined. This is because the case-fatality rates among pill users who had a hemorrhagic stroke were higher than among never users (Table 5) . Table 6 details the effect of use of oral contraceptives stratified by smoking history. Among the nonsmokers, current users had a significantly increased risk of all strokes but not of fatal strokes; former users did not appear to have an elevated risk. In contrast, among the women who smoked, both current and former users of the pill had a significantly increased risk of all stroke and of fatal episodes. There was insufficient power to test formally for statistical interaction between smoking and pill effects.
There was no effect of duration or time since stopping the pill (recency) on risk of first-ever stroke (data not shown). Table 7 examines the relation between use of oral contraception, diagnosis of hypertension, and subsequent stroke. Women who used the pill after a documented diagnosis of hypertension had a risk of subsequent stroke similar to that of hypertensive women who had never used oral contraceptives. Compared with this fivefold risk, however, stroke appeared to be less likely in women who stopped the pill during the same month as they were reported to have hypertension (adjusted OR, 1.5; 95% CI, 0.5 to 5.0). .08
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Cl indicates confidence interval. Odds ratios (ORs) adjusted for smoking, social class, and use of oral contraceptives, except where an adjusting variable Is itself being examined. History of hypertension also adjusted for history of toxemia of pregnancy and vice versa.
The effect of the particular pill preparation used at the time of the stroke is shown in Table 8 . The effect of the progestogen content was investigated first by examining the experience of women who used a series of pills in which 50 fig of ethinyl estradiol was combined with a varying dose of the progestogen norethindrone acetate. The preparations with a higher dose of progestogen were more strongly associated with stroke than lowerdose formulations (test for trend: ^2=10.6, P<.01). A second analysis compared brands that contained other progestogens in combination with differing doses of the estrogen ethinyl estradiol or mestranol. The dose of progestogen was ignored in this analysis. Pills containing the progestogens norethindrone acetate, lynestrenol, and ethynodiol diacetate were all associated with an elevated risk of stroke, in contrast to those containing levonorgestrel or other progestogens. When the brands were examined by the estrogen content of the pill (ignoring the effect of the various types and dose of accompanying progestogen), women who were using formulations with a high content were more likely to have a stroke than those on lower-dose preparations (test for trend: * 2 =7.5, P<.01).
Discussion
This investigation found that smoking, social class, and history of hypertension were important risk factors for stroke in women. Use of oral contraceptives was also associated with an increased risk of stroke. The data suggest that this effect of pill use was limited mainly to smokers.
Potential Limitations
Approximately 63% of the original cohort has been lost to general practitioner follow-up, mainly because the women have moved from the practice area of the recruiting doctor. Those no longer under observation tend to be younger, of lower parity, and of higher social class than those remaining in the study. The characteristics of pill users who have been lost to follow-up, however, are very similar to those of never users who have also been lost, and therefore comparisons between the contraceptive groups are still valid. In addition, in 1976 75% of the original cohort were flagged at the National Health Service Central Registry so that the study could be notified of any deaths occurring in women no longer under general practitioner observation. Analyses of 20-year mortality data show no difference in pattern between those who died after loss to cohort follow-up and those who died while still under observation. Such data suggest that the loss to follow-up has not resulted in major bias. The study was not subject to recall bias because the data on risk factors were collected prospectively. The Oral Contraception Study is an observational natural history study and does not set specific diagnostic criteria for any condition reported by the participating general practitioners. This might create a problem if the doctor's knowledge of the woman's exposure to the pill or other known risk factors was likely to influence the clinical diagnosis. For instance, stroke might be diagnosed more often in women known to have used oral contraceptives. There is evidence to suggest that this has not happened. First, the doctors often based their reports on additional information, such as results of hospital investigations, operation notes, consultant opinion, postmortem reports, or death certificates issued by the hospital. This supplementary information was available equally among women who had used the pill and those who had not (52% in each group). Second, the additional information was more likely to be available for fatal than nonfatal stroke (79% versus 44%), and yet the risk estimates associated with pill use were generally greater for fatal events than all episodes of stroke. A spurious association between current use of the pill and less severe stroke remains a possibility, although it seems unlikely that it would explain the observations in former users.
The clinical distinction between hemorrhagic and nonhemoirhagic stroke is unreliable. 15 Despite this, the pattern of case-fatality rates seen in the Oral Contraception Study (high for hemorrhagic stroke and low for thromboembolic events) was similar to that observed in the Oxfordshire Community Stroke Project, during .07
Cl Indicates confidence interval. Odds ratios (ORs) adjusted for smoking and social class. which most case subjects had neurological examination and full investigation. 16 Cases of vertebrobasilar insufficiency and drop attack were excluded from our study because some general practitioners appeared to use these diagnostic terms for vasovagal rather than cerebrovascular episodes. Users of the pill were no more likely to be assigned these diagnostic labels than those who had never used the pill.
Information on daily cigarette consumption has not been updated since the start of the Oral Contraception Study. Some of the increased risk in pill users might be due to a different rate of cessation of smoking among pill users compared with never users. However, if the behavior of each contraceptive group was similar and reflected national trends of decreasing prevalence of smoking, 17 our observations would have tended to underestimate the effect of smoking. The cohort study has not collected data on other characteristics, such as alcohol consumption or physical activity, that at least in men' 8 -19 have been found to be risk factors for stroke. It is possible that some of the effects of the pill could be explained by such potential confounders.
Other Studies
The increased risk of stroke among smokers and women with elevated blood pressure is in broad agreement with other studies. 20 ' 21 There have been few long-term investigations into the nonhypertensive cardiovascular sequelae of toxemia of pregnancy. We have previously reported a threefold increased risk of myocardial infarction in women with a prior diagnosis of toxemia of pregnancy.
11 Therefore, it was reassuring to find in this study a lower risk of stroke in relation to toxemia, although a threefold increase in risk of hem- Cl indicates confidence interval; EE, ethinyl estradiol. Odds ratios (ORs) adjusted for smoking and norethindrone brands containing 50 fig EE (4 mg, 3 mg, 1 mg, rest of the women): x orrhagic stroke associated with a history of preeclampsia has recently been reported by other investigators. 8 In our study current users of oral contraceptives had an increased risk of thromboembolic strokes and a more modestly elevated risk of hemorrhagic strokes. This pattern of risk is similar to that found by other investigators. 5 -2227 Former users had a small elevation in risk of all stroke that was not statistically significant, but they had a stronger risk of fatal stroke. Most other studies of past use of the pill have not shown such an increased risk. 38 The exception was the Walnut Creek Contraceptive Drug Study, which found an elevated incidence of subarachnoid hemorrhage among former users. 2 In our study the effects in former users appeared to be restricted to women who smoked. There was insufficient power to exclude an effect in nonsmokers, and further data are needed to confirm or refute these observations. Other investigators, however, have found an enhanced risk of hemorrhagic stroke among pill users who smoke.
2
- 28 In addition, there is evidence of interaction between smoking and use of the pill in relation to coronary disease.
-29
Implications
The data that relate to reported diagnosis of hypertension are difficult to interpret. This is partly because the number of women in some of the subgroups was small and partly because we had no information about the extent of the detection and control of hypertension. Hypertensive women who continued to use the pill did not appear to have a higher risk of stroke than hypertensive never users, although both hypertension and current use of the pill were clear independent risk factors in our study. Women who had a first-ever diagnosis of hypertension when using oral contraceptives and who stopped immediately appeared to have a lower risk of subsequent stroke than other hypertensive women in the study. This is consistent with the concept of a benign, reversible, pill-related hypertension. Other workers have shown that some women have pill-induced rises in blood pressure while they use oral contraceptives, an effect that usually resolves when the pill is no longer used. 30 Like the data relating to hypertension, those relating to the hormonal content of the pill used at the time of stroke should be interpreted with care. First, it has been assumed that any effects of previous brands disappear as soon as the pill is changed or no longer used. Second, the complex interaction between the type and dose of hormones contained in each pill was not examined, apart from the analyses of brands containing 50 ng of ethinyl estradiol and varying doses of norethindrone. It is possible, therefore, that the risk estimates associated with pills containing norethindrone, lynestrenol, and ethynodiol diacetate were elevated because these progestogens were combined with high doses of estrogen. In contrast, oral contraceptives with levonorgestrel were second generation low-dose preparations, which rarely contained more than 35 fig of ethinyl estradiol. Third, the number of events in each group was small, and therefore the analysis could be missing an important elevation in risk associated with the use of a particular brand of pill. Bearing these reservations in mind, our results provide tentative evidence that the risks of stroke are reduced by the use of low-dose formulations. Certainly the observations cannot be explained by the preferential use of low-dose pills by low-risk women, because the risk estimates were adjusted for smoking and social class. In addition, the method of matching case subjects to control subjects by time of event and age should take into account any secular trends that may have occurred, such as the increasingly careful selection of patients to whom the pill has been prescribed. 2 The study is unable to provide any information about recently introduced preparations that contain the new generation of progestogens, the risks of which have yet to be determined.
In 1990 the death rates from stroke among women aged 15 to 45 years in England and Wales was approximately 30 per million. 31 On the basis of our estimates of relative risk, the number of extra deaths observed among current users of the pill will be small. Mortality rates are much higher in those aged older than 45 years, and therefore an effect in former users persisting beyond this age would be associated with a greater excess risk. There is some evidence from our study to suggest that former users do have an increased risk of stroke, although the effects may be restricted to those who smoke. Further research is needed to clarify these observations, but they give further support to the recommendation that pill users should be warned of the dangers of smoking.
